Aquestive Therapeutics, Inc. (AQST)
| Previous Close | 3.3650 |
| Open | 3.4000 |
| Bid | 3.2200 x 700 |
| Ask | 3.2800 x 100 |
| Day's Range | 3.2150 - 3.4099 |
| 52 Week Range | 1.2510 - 6.2300 |
| Volume | |
| Avg. Volume | 2,839,408 |
| Market Cap | 294.965M |
| Beta (5Y Monthly) | 2.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1300 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.13 |
ZacksCarisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
CARISMA THERAP (CARM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksAnalysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireAquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients ages 2 to 5Announces immediate availability of Libervant 5mg, 7.5mg, 10mg, 12.5mg, and 15mg for patients between 2 to 5 years of ageCompany track record now includes 4 FDA approvals since 2018Anaphylm program on track; NDA submission expected by the end of 2024Hosts conference call for investors on April 29 at 8:00 a.m. ET WARREN, N.J., April 29, 2024 (GLOBE NEWSWIRE)
